Please assess the completion status of the following clinical trial:

Trial Title: Initial Versus Delayed PDT Combination With Conbercept in PCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Either gender，age ≥ 40.~2. BCVA at study entry of 34 to 79 letters (Snellen Equivalent 20/200 to 20/25).~3. Naive symptomatic PCV patients.~4. Presence of PCV assessed based on ICG with active polyps with or without abnormal vascular network.~5. No refractive media opacity or small pupil narrow that influence the fundus examination.~6. Women must be using effective contraception, be post-menopausal for at least months prior to trial entry, or surgically sterile.~7. Ability to provide written informed consent and to return for all study visits.~Exclusion Criteria:~1. Active inflammation or infection in the study eye.~2. Uncontrolled intraocular pressure (\>25 mmHg) in the study eye.~3. Ocular condition in the study eye which may impact vision and confound study outcomes (e.g. vitreomacular traction, epiretinal membrane with BCVA impact, ocular inflammation, retinal vascular diseases like diabetic retinopathy or diabetic macular edema).~4. Presence of centro macular scarring or atrophy indicating irreversible BCVA loss.~5. Prior treatment of the study eye with anti-VEGF therapy or systemic use of anti-VEGF products within 3 months prior to the study entry.~6. Previous vitrectomy, macular laser treatment, PDT, or intraocular steroids in the study eye.~7. Allergy to fluorescein, ICG, iodine, shellfish.~8. Pregnant or breast-feeding women.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Initial PDT combination with Conbercept (Type: EXPERIMENTAL): 1. Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~2. PDT: PDT with verteporfin is administered at baseline and then PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months.
- Delayed PDT combination with Conbercept (Type: ACTIVE_COMPARATOR): 1. Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~2. PDT:PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).